Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
K-Tropix Review
Its own product copy says mitragynine mimics opioid drugs. Its advertorials say it relieves pain, anxiety and depression. Both cannot be a responsible way to sell the same thing.
K-Tropix
Opioid-Receptor AgonistRead this first, in the company's own words: mitragynine “mimics the effects of opioid drugs”, and “The US FDA has not approved mitragynine as a dietary supplement”. Both statements are on K-Tropix's own site. Kratom causes physical dependence and an opioid-type withdrawal syndrome — that is the primary documented harm, not a fringe risk.
Yet the advertorials say otherwise. One landing page is headlined “Breakthrough One-Shot Boost For Relieving Pain & Anxiety”, with body copy about “Relieving Pain, Anxiety, And Depression” — disease claims contradicting the disclaimer on the same page. And KODE is sold as an “Enhanced Kratom Shot” at 150mg per 10ml, in Rocket Pop flavour pitched at “those new to the plant”.
The federal position is moving now: FDA recommended scheduling 7-OH in July 2025, HHS and FDA commended DEA's Notices of Intent on 1 July 2026, and a Federal Register notice dated 6 July 2026 covers temporary Schedule I placement of 7-hydroxymitragynine above a threshold — aimed at concentrated and enhanced products, not plain leaf. FDA reporting on 7-OH: 79 of 86 cases serious, including death, mostly dependence and withdrawal.
Affiliate disclosure: GLP1Drugs.org earns a commission if you buy through the links on this page — and you should know this programme pays 30% plus 10% recurring, the highest rate in our entire queue. We are recommending against it anyway. Verified 8 August 2026. Age 21+ where lawful.
Visit K-TropixOur Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
79/86
7-OH Cases Serious, Incl. Death
150mg
Mitragyna In One 10ml Shot
6 Jul
2026 Federal Register Notice
30%
Commission This Pays Us
What The Company Says, And What The Record Says
Six findings — two crediting unusual candour, four documenting the problem.
It Says Itself That This Acts Like An Opioid
K-Tropix's own product copy states that mitragynine 'mimics the effects of opioid drugs'. That is accurate pharmacology, unusually candid for the category, and the single most important fact about what is being sold
And That FDA Has Not Approved It
The homepage states: 'The US FDA has not approved mitragynine as a dietary supplement.' It lists states where it does not ship, requires purchasers to be 21, and commits to publishing a certificate of analysis for every batch
But The Advertorials Claim Pain, Anxiety And Depression
One landing page is titled 'Breakthrough One-Shot Boost For Relieving Pain & Anxiety', with body text about 'Relieving Pain, Anxiety, And Depression'. Those are disease claims, and they contradict the disclaimer on the same page
The 'Enhanced' Shot Is In The DEA's Crosshairs
KODE is sold as an 'Enhanced Kratom Shot' with 150mg of Mitragyna per 10ml bottle. DEA's July 2026 Notices of Intent target enhanced kratom products with higher amounts of 7-OH and mitragynine
The Federal Position Is Moving Right Now
A Federal Register notice dated 6 July 2026 covers temporary placement of 7-hydroxymitragynine above a specified threshold in Schedule I. FDA recommended scheduling 7-OH in July 2025; HHS and FDA commended DEA's action on 1 July 2026
The Adverse Event Signal Is Dependence And Death
FDA reporting on 7-OH showed 66 cases in 2025 and 17 more by February 2026 — 79 of 86 total classed as serious, including death, with most involving drug dependence and withdrawal syndrome
Why This Is Worse Than Usual On A GLP-1
Three specific overlaps, not a general caution. Each one compounds something your medication already does.
| Effect | From kratom | Already caused by GLP-1s |
|---|---|---|
| Slowed gut / constipation | Mu-opioid agonism reliably slows transit | Delayed gastric emptying; constipation is common |
| Nausea and vomiting | Common, and dose-related | Very common during dose escalation |
| Liver injury | Kratom-induced liver injury is documented | Fatty liver disease is highly prevalent in this population |
| Dependence and withdrawal | The dominant reported harm in FDA data | Withdrawal can be mistaken for treatment side effects |
The practical consequence of the last row: if you use kratom and your clinician does not know, symptoms that are actually withdrawal or kratom toxicity get attributed to your medication — and your dose may be reduced or your treatment stopped for the wrong reason. Tell them. Our side-effects guide covers what is normal during titration, and our provider rankings cover finding a service that actually reviews what else you are taking.
Pros & Cons
Pros
- ✓Unusually candid on the central pharmacology: its own product copy states mitragynine 'mimics the effects of opioid drugs'
- ✓The homepage states plainly that 'The US FDA has not approved mitragynine as a dietary supplement'
- ✓A 21-and-over purchase requirement is stated for mitragynine products
- ✓It publishes a list of states where it will not ship because mitragynine is banned, including Alabama, Arkansas, Indiana, Rhode Island, Vermont and Wisconsin
- ✓It commits to publishing a certificate of analysis for every batch sold, stating you can read the lab work before you buy
- ✓GMP certification and lab testing are claimed across the range
- ✓The FDA disclaimer is present, stating products are not intended to diagnose, prevent, treat or cure any disease
- ✓It publishes explanatory content about changing state kratom law, including South Carolina's 2025 age-restriction legislation and Louisiana Senate Bill 154
- ✓Serving sizes are stated concretely — 150mg of Mitragyna per 10ml KODE shot, 30mg of extract per softgel with 25 per bag
- ✓The advertorial pages are at least labelled 'Advertorial' rather than passed off as independent journalism
Cons
- ✕Advertorial landing pages promise relief of pain, anxiety and depression — disease claims for a substance with opioid-receptor activity
- ✕Those claims sit on the same pages as a disclaimer saying the products are not intended to treat any disease, which is a direct contradiction
- ✕The KODE product is branded an 'Enhanced Kratom Shot', which is the exact product category DEA's 2026 Notices of Intent target
- ✕A Federal Register notice dated 6 July 2026 concerns temporary Schedule I placement of 7-hydroxymitragynine above a specified threshold
- ✕FDA adverse event data on 7-OH is dominated by drug dependence and withdrawal syndrome, with 79 of 86 cases classed as serious including death
- ✕Kratom causes physical dependence and an opioid-type withdrawal syndrome; this is the primary documented harm, not a fringe risk
- ✕Marketing an opioid-receptor agonist in 'Rocket Pop' flavour as 'appealing' to 'those new to the plant' lowers the barrier to first use
- ✕Product copy promising 'consistent results without ever increasing dosage' cuts against the known tolerance profile of this substance
- ✕Kratom-induced liver injury is documented, which matters given how common fatty liver disease is in people carrying excess weight
- ✕Opioid-receptor activity causes constipation, and GLP-1 medicines already slow gut transit — the combination is a real risk
- ✕Methylene blue is sold as a consumer nootropic at $29.97; it has monoamine oxidase inhibitory activity and serotonin syndrome risk with serotonergic drugs
- ✕No age gate appeared on the homepage — the 21-plus requirement is written as text rather than enforced before browsing
- ✕No Trustpilot rating was retrievable and no BBB profile came up, so independent signal is absent
- ✕This programme pays 30% commission plus 10% recurring, the highest rate in our entire affiliate queue
Our Verdict
1.9 / 5 — more honest than most kratom sellers about what this is, and advertising it for exactly the conditions it should not be advertised for.
Credit first, because there is some and it is unusual. K-Tropix states on its own homepage that 'The US FDA has not approved mitragynine as a dietary supplement.' Its own product copy states that mitragynine 'mimics the effects of opioid drugs', and it names 7-hydroxymitragynine among the active alkaloids. It requires purchasers to be 21, publishes a list of states it will not ship to because mitragynine is banned there, commits to publishing a certificate of analysis for every batch so you can read the lab work before buying, claims GMP certification, carries the FDA disclaimer, and even publishes explanatory coverage of new state legislation. Several kratom sellers do none of that. If you are going to buy kratom, disclosure of that kind is worth something real.
Then there are the advertorials. One landing page supplied to affiliates is headlined 'Breakthrough One-Shot Boost For Relieving Pain & Anxiety', and its body copy reads 'How This Breakthrough One-Shot Boost For Relieving Pain, Anxiety, And Depression Helped Me'. Those are three diagnosable conditions, and the same page carries a disclaimer stating the products are not intended to diagnose, prevent, treat or cure any disease. A company cannot simultaneously tell you that a compound acts like an opioid and that it relieves depression, and expect a reader to hold both. People searching for help with depression and anxiety are precisely the people who should not be steered toward a dependence-forming mu-opioid agonist. Alongside that sits KODE, an 'Enhanced Kratom Shot' at 150mg of Mitragyna per 10ml, in Rocket Pop flavour, described as appealing to 'those new to the plant' — a concentrated dose of an opioid-receptor agonist made to taste like a childhood ice lolly and marketed to beginners.
The regulatory and safety record closes the case. FDA recommended scheduling 7-OH in July 2025; HHS and FDA commended DEA's Notices of Intent on 1 July 2026; a Federal Register notice dated 6 July 2026 concerns temporary Schedule I placement of 7-hydroxymitragynine above a specified threshold — and the action targets exactly the enhanced, concentrated products this company sells, not plain leaf. FDA's adverse event data on 7-OH recorded 66 cases in 2025 and 17 more by February 2026, with 79 of 86 classed as serious including death, and dependence and withdrawal syndrome the dominant problem. For readers of this site there are three further overlaps: kratom slows the gut and so do GLP-1s, kratom causes nausea and so does titration, and kratom-induced liver injury lands on a population where fatty liver is common. Separately, the methylene blue product sold here has monoamine oxidase inhibitory activity and a serotonin syndrome risk with common antidepressants and triptans. We are disclosing that this programme pays 30% plus 10% recurring — the highest in our queue — and recommending against it regardless.
Visit K-TropixFrequently Asked Questions
What is kratom and what does it actually do?
It is a plant whose active compounds act on opioid receptors, and K-Tropix says so itself — which is the most useful sentence on its website. Kratom is Mitragyna speciosa, a Southeast Asian tree. Its principal alkaloid is mitragynine, and a minor but far more potent one is 7-hydroxymitragynine, usually abbreviated 7-OH. Both are partial agonists at the mu-opioid receptor, which is the same receptor morphine and oxycodone act on. K-Tropix's own product description for one of its powders states that mitragynine 'mimics the effects of opioid drugs', and elsewhere it names 7-hydroxymitragynine as among the alkaloids responsible for the effects. That candour is genuinely unusual in this market and we credit it. What follows from it is the whole reason for caution. At lower doses users typically report stimulation and alertness; at higher doses sedation and analgesia. And like other mu-opioid agonists it produces physical dependence with repeated use, followed by a withdrawal syndrome on stopping — irritability, muscle aches, insomnia, sweating, nausea, restlessness and craving. That is not a rare complication. In FDA's adverse event reporting on 7-OH, dependence and withdrawal syndrome were the dominant reported problems.
Is kratom legal, and is that changing?
The plant is not federally scheduled, the concentrated form is being scheduled right now, and the picture varies by state. Taking those in order. Ordinary kratom leaf and mitragynine are not currently federal controlled substances, which is why these products are sold openly. But in July 2025 the FDA recommended to the DEA that 7-hydroxymitragynine — the potent minor alkaloid, not the plant — be placed in Schedule I. On 1 July 2026 HHS and FDA publicly commended the DEA for issuing two Notices of Intent beginning the temporary scheduling process for certain kratom-related substances, and a Federal Register notice dated 6 July 2026 concerns the temporary placement of 7-hydroxymitragynine above a specified threshold in Schedule I. The action is aimed at concentrated, enhanced and semi-synthetic products rather than at plain leaf — a distinction that matters and that we want to state precisely. At state level, K-Tropix itself lists jurisdictions where it will not ship because mitragynine is banned, naming Alabama, Arkansas, Indiana, Rhode Island, Vermont and Wisconsin among others, and it publishes coverage of new laws in South Carolina and Louisiana. So: legal in most of the country today, banned in several states, and with the concentrated end of the market actively being scheduled as we write on 8 August 2026.
Why does the 'Enhanced' shot concern you specifically?
Because the word 'Enhanced' names the exact category the federal action is aimed at. K-Tropix sells KODE as an 'Enhanced Kratom Shot' containing 150mg of Mitragyna in each 10ml bottle. The DEA's 2026 Notices of Intent, as described in the accompanying federal commentary, target enhanced kratom products containing higher amounts of 7-OH and mitragynine, and synthetic 7-OH-related substances — not ordinary leaf. A product marketed on the strength of being enhanced, delivering a concentrated alkaloid dose in a 10ml shot, is squarely the shape of product that regulatory attention is directed at. Two further things about how it is sold. It is flavoured 'Rocket Pop' and the copy describes the taste as combining 'sweetness and nostalgia', explicitly presenting it as 'an appealing choice for both experienced kratom users and those new to the plant'. Making an opioid-receptor agonist taste like a childhood ice lolly, and pitching it at first-time users, lowers the threshold to starting something that causes dependence. And the range elsewhere promises 'consistent results without ever increasing dosage', which sits awkwardly against the well-documented tolerance that develops with opioid-receptor agonists. If you are going to use kratom at all, a concentrated enhanced shot is the wrong end of the market to start at.
What is wrong with the advertorials?
They make disease claims that the disclaimer on the same page denies. Two of the landing pages supplied to affiliates are advertorials. One is titled 'Breakthrough One-Shot Boost For Relieving Pain & Anxiety', and its body text reads 'How This Breakthrough One-Shot Boost For Relieving Pain, Anxiety, And Depression Helped Me'. Pain, anxiety and depression are all diagnosable medical conditions. A dietary supplement may make structure-function claims but may not claim to treat, mitigate or prevent a disease — doing so makes it an unapproved drug in the FDA's framework. And the same pages carry the disclaimer that 'The products mentioned on this website are not intended to diagnose, prevent, treat or cure any diseases or health conditions', which is the standard formula and which the headline directly contradicts. To be fair on one point: the pages are labelled 'Advertorial', so they are not disguised as independent journalism, and that is better than the alternative. But the substantive problem is not the format. It is that a substance which acts on opioid receptors and whose dominant reported harm is dependence is being advertised as relief for depression and anxiety — conditions for which people are actively looking for help, and for which an opioid-like compound is a particularly poor and risky self-treatment.
Is it safe to take kratom while on a GLP-1?
We would advise against it, and there are three specific reasons rather than a general one. First, constipation. Mu-opioid receptor agonism slows gastrointestinal transit — it is why opioid painkillers cause constipation so reliably. GLP-1 receptor agonists also slow gastric emptying and transit, and constipation is one of their commonest side effects. Combining two agents that both slow the gut is a genuine risk of severe constipation and, at the extreme, obstruction. Second, symptom confusion. Kratom causes nausea and vomiting, and so does GLP-1 dose escalation. If you are being sick and taking both, your clinician cannot work out which is responsible unless you tell them about the kratom, and people frequently do not because they assume a plant product is not worth mentioning. Third, the liver. Kratom-induced liver injury is documented in the clinical literature, typically presenting weeks into use with jaundice, itching and abnormal liver enzymes. That matters here because fatty liver disease is highly prevalent in people carrying excess weight, so many readers already have a liver under strain. Add that kratom's dominant harm is dependence, and that stopping it produces an opioid-type withdrawal that could easily be mistaken for something else during treatment. Tell your prescriber if you use it. It is a clinical fact, not a confession.
What about the methylene blue product?
That is a separate and genuinely serious concern, and it deserves flagging even though it is not kratom. K-Tropix sells Methylene Blue plus Vitamin C at $29.97 as a dropper solution, marketed for 'cellular energy', mitochondrial function, focus and immune support, and described as USP-grade with 'the nootropic power of methylene blue'. Methylene blue is not an ordinary supplement ingredient. It is a pharmaceutical agent, used clinically by injection to treat methaemoglobinaemia, and it has monoamine oxidase inhibitory activity. That is the crux: methylene blue combined with serotonergic drugs can precipitate serotonin syndrome, a potentially life-threatening reaction, and the FDA has previously warned about this specific interaction. The relevant serotonergic drugs are extremely common — SSRIs and SNRIs, tricyclics, triptans for migraine, tramadol, and others. A person taking sertraline or venlafaxine, which is a very large number of people, should not be dropping methylene blue into their morning water on the strength of a nootropic claim. It can also cause a false reading on pulse oximetry and turns urine blue-green, which is harmless but alarming. If you take any antidepressant, any migraine triptan, tramadol, or any other serotonergic medicine, do not buy this without speaking to a pharmacist or prescriber first.
Are the lab certificates any good?
The commitment is the right one and we could not put it to the test in this review. K-Tropix states on its homepage that it publishes 'a Certificate of Analysis for every batch we sell, so you can read the lab work before you buy', and that all products are 'GMP Certified and Lab Tested'. Per-batch certificates published before purchase is exactly the correct standard, and it is more than several brands we have reviewed manage — we have opened batch links elsewhere that returned nothing at all. What would matter most for kratom specifically is a panel covering alkaloid content, particularly mitragynine and 7-OH percentages, plus heavy metals and microbiology. Both of those contaminant categories are documented problems in this product class: the FDA has reported heavy metals including lead and nickel in kratom products, and there was a multistate salmonella outbreak linked to kratom several years ago. So before buying, the questions to ask are specific: what is the mitragynine content and the 7-OH content of my batch, and does the certificate include heavy metals and microbial testing? A potency-only certificate would not answer the contamination question. Ask for the full panel for your batch and read the 7-OH figure in particular, given what is happening federally with concentrated 7-OH products.
Does any of this help with weight?
No, and if anything the risk runs the other way. K-Tropix does not market these products for weight loss and we found no weight claims, which is to its credit. But the question arises because kratom is sometimes discussed as an appetite suppressant, and because people looking for energy while eating less might land on a product like this. Two points. Opioid-receptor agonists can reduce appetite and cause nausea, so a subjective appetite effect is plausible — but using a dependence-forming opioid-like substance as an appetite aid is a straightforwardly bad trade, and you already have a far more effective and far better studied appetite intervention if you are on a GLP-1. Second, the stimulant framing at lower doses is largely being sold as a caffeine alternative, and one of the advertorials is built entirely around replacing coffee. If jitteriness from caffeine is your actual problem, the solution is less caffeine, not a mu-opioid agonist. Nothing here supports weight management, nothing here protects lean mass, and the constipation and nausea it can cause work directly against tolerating GLP-1 treatment. If weight is what brought you here, our provider rankings and side-effects guide are the pages worth your time.
Who should buy this, and what would you tell them?
We would not recommend this category to anyone reading a weight-management site, and we want to be plain rather than coy about it. If you are already a settled kratom user, live in a state where it is lawful, are over 21, and are going to buy regardless, then K-Tropix discloses more than most of its competitors: it states that FDA has not approved mitragynine, it states that mitragynine mimics opioid drugs, it lists banned states, it requires you to be 21, and it commits to per-batch certificates. Ask for the full certificate for your batch including 7-OH content, heavy metals and microbiology. Avoid the concentrated 'Enhanced' shot in particular, both because it is the category under active federal scheduling and because concentrated alkaloid doses are where dependence accelerates. Do not buy it if you take a GLP-1, because of the compounding constipation and nausea and the confusion it creates in your clinical picture. Do not buy it on the strength of the advertorials, because relieving depression and anxiety is not something an opioid-receptor agonist should be sold for. Do not buy the methylene blue if you take any antidepressant, triptan or tramadol. And if you are already using kratom daily and thinking about stopping, speak to a clinician, because withdrawal from a mu-opioid agonist is a medical issue and there is help for it.
If You Already Use It, Tell Your Prescriber
Kratom withdrawal and kratom toxicity get misattributed to your medication if nobody knows you take it — and your dose may be cut for the wrong reason. It is a clinical fact, not a confession.
Visit K-TropixCompare Other GLP-1 Providers
See how other telehealth providers stack up.
Boston Medical Group
Top RatedEstablished telehealth provider with physician oversight and transparent pricing
Read Review →Alan Meds
Top RatedAffordable compounded GLP-1s with board-certified physicians and straightforward pricing
Read Review →Form Health
Comprehensive ProgramMultidisciplinary obesity medicine program with physicians, dietitians, and behavioral coaching
Read Review →BeyondMD
Top RatedBoard-certified physician-led care with comprehensive medical oversight
Read Review →Mochi Health
Obesity Medicine SpecialistsBoard-certified obesity medicine specialists with both brand-name and compounded GLP-1 options
Read Review →LifeMD
Top RatedPublicly traded telehealth company with comprehensive health platform and competitive pricing
Read Review →Medical & Safety Disclaimer: This page is informational and is not medical advice. Kratom is not approved by the FDA for any medical use and is not approved as a dietary supplement. Its principal alkaloids mitragynine and 7-hydroxymitragynine are partial agonists at the mu-opioid receptor; kratom causes physical dependence with repeated use and an opioid-type withdrawal syndrome on cessation, and dependence and withdrawal are the dominant harms in FDA adverse event reporting on 7-hydroxymitragynine, which also includes deaths. Kratom-induced liver injury is documented; seek urgent medical attention for jaundice, dark urine, pale stools, severe itching, right upper abdominal pain or unexplained vomiting. Kratom should not be combined with opioids, benzodiazepines, alcohol or other sedatives, and has been implicated in deaths where other substances were also present. Do not use if pregnant or breastfeeding, or if under 21. Opioid-receptor agonism slows gastrointestinal transit and can compound the constipation caused by GLP-1 receptor agonists; seek medical advice for severe abdominal pain, vomiting, or inability to pass stool or wind. Tell your prescriber if you use kratom, because withdrawal and toxicity can be mistaken for medication side effects. If you use kratom daily and wish to stop, seek clinical support. Methylene blue has monoamine oxidase inhibitory activity and can precipitate serotonin syndrome when combined with serotonergic medicines including SSRIs, SNRIs, tricyclic antidepressants, triptans and tramadol; it can also interfere with pulse oximetry readings. Do not take methylene blue without speaking to a pharmacist or prescriber if you take any such medicine. Legal status varies by state and is changing; verify the position where you live. Consult a licensed clinician before starting or changing any treatment.
Date reviewed: 8 August 2026. Prices, product descriptions and site statements were read from ktropix.com and its public product catalogue on that date and may change: PURE Series powders $19.97–$74.97 and capsules $24.97–$84.97, strain powders (Green Maeng Da, White Maeng Da, White Sumatra, White Borneo, Green Malay) $19.97–$74.97 with capsules $24.97–$84.97, Kratom softgels $49.97 stated as 25 softgels each containing 30mg of kratom extract, Kratom Shot bundles $36.51–$100.00, Kava Shot bundles $12.72–$100.00, KODE Enhanced Kratom Shot $11.99–$115.10 described as '150mg of Mitragyna speciosa in each 10ml bottle' in Rocket Pop flavour, Methylene Blue + Vitamin C $29.97–$112.08, and Klean Protein and Klean + Caffeine products. Quoted site wording is K-Tropix's own: 'The US FDA has not approved mitragynine as a dietary supplement'; 'Must be 21 years or older to purchase mitragynine'; 'We do not ship to the following states, cities and counties in the US where mitragynine is banned: Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisc…'; 'We publish a Certificate of Analysis for every batch we sell, so you can read the lab work before you buy'; 'All our products are GMP Certified and Lab Tested'; 'Its primary active ingredient, mitragynine, mimics the effects of opioid drugs'; that Green Maeng Da has 'high and precise alkaloid concentrations, particularly of mitragynine and 7-hydroxymitragynine'; 'Consistent results without ever increasing dosage'; and the KODE copy describing 'an appealing choice for both experienced kratom users and those new to the plant'. The advertorial pages were titled 'Advertorial - Breakthrough One-Shot Boost For Relieving Pain & Anxiety' with body text 'How This Breakthrough One-Shot Boost For Relieving Pain, Anxiety, And Depression Helped Me', and carried the disclaimer 'The products mentioned on this website are not intended to diagnose, prevent, treat or cure any diseases or health conditions'. No age gate appeared before browsing on the homepage. Regulatory chronology: in July 2025 the FDA recommended to the DEA that 7-hydroxymitragynine, not the kratom plant, be placed in Schedule I; on 1 July 2026 HHS and FDA commended the DEA's issuance of two Notices of Intent beginning temporary scheduling of certain kratom-related substances; a Federal Register notice dated 6 July 2026 concerns the temporary placement of 7-hydroxymitragynine above a specified threshold in Schedule I; the notices target concentrated, enhanced and semi-synthetic products rather than ordinary kratom leaf or mitragynine. FDA adverse event reporting on 7-hydroxymitragynine covering June 2023 to June 2025, with a database query of 27 February 2026, recorded 66 cases for 2025 and 17 new cases for 2026, with 79 of 86 total cases reported as serious including death, most involving drug dependence and withdrawal syndrome. No Trustpilot aggregate rating was retrievable and a BBB search returned no profile. The Katalys offer lists 30.00% default commission and 10.00% recurring.
Affiliate Disclosure: This site may receive compensation from affiliate partners. This programme pays 30% commission plus 10% recurring, the highest rate in our affiliate queue. We recommend against these products regardless. This does not influence our editorial content or review ratings.